|
October 2, 2008: VentriPoint Diagnostics LTD. engages CHF investor relations September 10, 2008: VentriPoint Diagnostics Announces Private Placement of Equity Financing August 29,2008: VentriPoint Diagnostics Files Management Discussion and July 1, 2008: VentriPoint Appoints Mary-Pierre Waiss Vice President of Clinical Development June 3, 2008: VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial May 8, 2008: Medical Device Daily: VentriPoint develops better method of RV measurement April 30, 2008: VentriPoint Diagnostics Files Management Discussion and Analysis, Audited Financial Results April 29, 2008: Knowledge Based Reconstruction Demonstrates Accuracy in
Obtaining Ventricular April 24, 2008: VentriPoint, University of Washington Sign Research March 2008: VentriPoint Diagnostics Announces the Committee Membership of its February 2008: VentriPoint Diagnostics Retains Russo Partners as Communications Counsel September 2007: VentriPoint goes public via a reverse merger with Luca Capital (stock symbol: VPT) April 2007: Luca to Acquire Ventripoint as Qualifying Transaction February 2006: Scientific Advisory Board created, initial membership: Dr. Mark Lewin, M.D. Seattle Children’s Hospital; Dr. Tom Jones, M.D. Seattle Children’s Hospital February 2006: Signed collaboration agreement with Zurich University to collect MRI data. January 2006: Treuman Katz joins the VentriPoint Board of Directors. January 2006: Key development team hired.
VentriPoint Diagnostics Ltd. is a public Canadian company with its common shares traded on the TSX Venture Exchange under the symbol "VPT", its only operations being those of VentriPoint, Inc. Complete and continuous disclosure documents, including audited financial statements can be found at: http://www.sedar.com/
|